MUC1-CEA-ERBB2-telomerase-BIRC5-MAGEA1-RNA-vaccine - CureVac

Drug Profile

MUC1-CEA-ERBB2-telomerase-BIRC5-MAGEA1-RNA-vaccine - CureVac

Alternative Names: mRNA RCC vaccine - CureVac; mRNA renal cell carcinoma vaccine - CureVac; Mucin-1 carcinoembryonic antigen ERBB2 telomerase BIRC5 MAGEA1 RNA vaccine; RNAactive RCC vaccine - CureVac; RNAactive renal cell carcinoma vaccine - CureVac; TAA mRNA vaccine - CureVac

Latest Information Update: 31 Mar 2015

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator CureVac
  • Class Cancer vaccines; RNA vaccines
  • Mechanism of Action Immunomodulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No

Highest Development Phases

  • No development reported Renal cancer

Most Recent Events

  • 13 Mar 2015 No development reported - Phase-I/II for Renal cancer in Germany (Intradermal)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top